Comment on "Simplification of Hematopoietic Stem Cell Transplantation and Continued FACT Accreditation: Strategies for Low- and Middle-Income Countries" [0.03%]
关于“造血干细胞移植的简化和持续FACT认证：低收入和中等收入国家的战略”一文的评论
Dr Anwar Khan,Usha Yada,Dr Pramila D&#x;Souza
Dr Anwar Khan
Exercise Duration During a Brief Step Test Independently Predicts Outcomes After Hematopoietic Cell Transplantation [0.03%]
简短台阶试验中的运动时间独立预测造血细胞移植后的预后
Zhenmei Zhang,Mehrdad Hefazi Torghabeh,William J Hogan et al.
Zhenmei Zhang et al.
Background: Pre-transplant pulmonary function testing (PFT) is standard before hematopoietic cell transplantation (HCT), but few centers complement it with objective functional capacity assessment. At our institution, a 3...
Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell Therapy: Clinical Characteristics and Impact on Mortality [0.03%]
嵌合抗原受体T细胞治疗后急性肾损伤的临床特点和对死亡风险的影响
Hadeel Jazieh,Abedalrahman Almashayekh,J Curran Henson et al.
Hadeel Jazieh et al.
Background: Chimeric antigen receptor T-cell (CAR-T) therapy is a breakthrough in hematologic malignancies but carries risks, including acute kidney injury (AKI). AKI may arise due to inflammatory responses like cytokine ...
Peri-transplant ruxolitinib prophylaxis improves outcome in patients receiving allogeneic hematopoietic cell transplantation for myelofibrosis [0.03%]
移植前使用鲁索利替尼预防可改善原发性髓纤患者的allo-HSCT预后
Miriam Mozaffari Jovein,Thomas Meyer,Miguel Waterhouse et al.
Miriam Mozaffari Jovein et al.
Comment on "Early Immunosuppression as CRS Prophylaxis in Outpatient Haploidentical Transplants: A Randomized Phase II Study" [0.03%]
关于“随机Ⅱ期临床研究：单倍型相合移植门诊隔离防护采用早期免疫抑制预防移植物抗宿主病和移植物衰竭”的评论
Candana Maji,Hariharan Srinivasan,Aishwarya Biradar et al.
Candana Maji et al.
Significance of CD34+ Cell Dose on Outcomes of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation in AML: An Analysis Stratified by MRD Status [0.03%]
MRD状态分层下CD34+细胞剂量对非清髓性allo-HSCT后AML患者预后影响的研究
Margery Gang,Megan Othus,Anne-Chloe Olix et al.
Margery Gang et al.
Background: Reduced toxicities with reduced-intensity and non-myeloablative conditioning (collectively, non-MAC) regimens have expanded access of allogeneic hematopoietic cell transplantation (HCT) to older and less fit a...
Prospective Validation of Multi-week Inpatient Census Forecasting for Pediatric HSCT and Cellular Therapy [0.03%]
儿科造血干细胞移植和细胞治疗多周住院人口预测的前瞻性验证
Ezra Porter,Richard S Hanna,Timothy S Olson et al.
Ezra Porter et al.
Background: Accurate inpatient census forecasting is important for cell therapy and blood and marrow transplantation (BMT) programs because bed capacity, staffing, and coordination of transplant care depend on anticipatin...
Rethinking Letermovir Strategy Beyond Day +100 for Late CMV Prevention After Allogeneic Hematopoietic Cell Transplantation [0.03%]
allo-HCT后晚期CMV预防：在+100天之后重新考虑Letermovir策略
Nihar Desai,Gonzalo Bentolila,Jonas Mattsson
Nihar Desai
Not applicable. Copyright © 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
ASCT, CAR T-cell, or Combined Consolidation for R/R PCNSL in Re-achieved CR: An Inverse Probability of Treatment Weighting-Adjusted Comparative Study [0.03%]
ASCT、CAR-T细胞或联合巩固治疗复发/难治PCNSL患者重新获得CR的比较研究：倾向评分加权分析
Fan Yang,Rui Liu,Zhonghua Fu et al.
Fan Yang et al.
Background: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising strategy for treating relapsed or refractory primary central nervous system lymphoma (R/R PCNSL). While recent reports suggest that com...
Comment on "Immune Reconstitution After Allogeneic Stem Cell Transplantation: Time Alone Does Not Heal All Wounds" [0.03%]
关于“同种异体干细胞移植后的免疫重建：时间并不能治愈所有的伤口”的评论
Yuling An,Wenjuan Li,Yuan Xie et al.
Yuling An et al.